IP Library › Granted Patent US 10,471,124
Granted Patent B2
US 10,471,124 · App. 15/528,909 · Granted Nov 12, 2019

Proteinaceous heterodimer and use thereof

Inventors: Ting Xu (Jiangsu, CN); Yan Luan (Jiangsu, CN); Jianjian Peng (Jiangsu, CN); Shuli Ma (Jiangsu, CN); Meng Zhao (Jiangsu, CN); Xiaoxiao Wang (Jiangsu, CN); Hui Ma (Jiangsu, CN); Shilong Fu (Jiangsu, CN); Xiaolong Pan (Jiangsu, CN); Shanshan Ning (Jiangsu, CN)
Assignee: DINGFU BIOTARGET CO., LTD.
A61K38/19C07K14/5428C07K14/56C07K14/565C07K16/2863C12N15/62C12N15/63A61K38/00C07K19/00C07K2317/92C07K2319/00C07K2319/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,471,124
App. No.
15/528,909
Granted
Nov 12, 2019
Kind
B2
Abstract

The present disclosure provides proteinaceous heterodimers, pharmaceutical compositions, medicaments and/or kits comprising the proteinaceous heterodimers, methods for producing the proteinaceous heterodimers, and uses thereof.

Claims (5)

1. A proteinaceous complex, comprising (i) a light chain and a heavy chain of an antibody; and (ii) a fusion polypeptide comprising, from N-terminus to C-terminus, an immunoregulator fused to an antibody Fc region, optionally via a linker;

wherein said light chain of the antibody and said heavy chain of the antibody respectively comprises an amino acid sequence as set forth in: SEQ ID NO: 11 and SEQ ID NO: 13, SEQ ID NO: 15 and SEQ ID NO: 17, SEQ ID NO: 55 and SEQ ID NO: 53, or SEQ ID NO: 65 and SEQ ID NO: 67; and

said fusion polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 1, SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7, SEQ ID NO: 9, SEQ ID NO: 49, or SEQ ID NO: 51.

2. The proteinaceous complex of claim 1 , wherein the immunoregulator is selected from the group consisting of interferon alpha, interferon lamda and interferon beta.

3. The proteinaceous complex of claim 1 , wherein the immunoregulator is interleukin 10.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2024
From: DINGFU BIOTARGET, CO., LTD.
To: SHIHUIDA PHARMACEUTICAL GROUP (JILIN) CO., LTD.
Reel/Frame 068654/0722 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 23, 2017
From: XU, TING; LUAN, YAN; PENG, JIANJIAN; MA, SHULI; ZHAO, MENG; WANG, XIAOXIAO; MA, HUI; FU, SHILONG; PAN, XIALONG; NING, SHANSHAN
To: DINGFU BIOTARGET CO., LTD.
Reel/Frame 042478/0055 →
Priority Claims (1)
CN 2014 1 0681422 · Nov 24, 2014 · national
Continuity (1)
Related Publication 20170340708A1 · Nov 30, 2017